The study focuses on people who have Severe asthma, a condition in which the airways are constantly narrowed and inflamed, making breathing difficult. Some participants also have chronic rhinosinusitis, a long‑lasting inflammation of the nose and sinus cavities that often occurs together with asthma. The medication being tested is tezepelumab, sold under the brand name Tezspire, and it is given by a subcutaneous injection, which means the drug is placed just under the skin using a small needle.
The purpose of the research is to compare how a protein called TSLP is produced in airway cells after they are exposed to a laboratory substance that mimics a virus, known as poly(I:C). Participants will have samples taken from their nose and lungs at the start of the study, receive the study medication, and then provide additional samples at later visits. The collected cells are placed in a lab where they are exposed to the viral mimic, and researchers measure changes in the amount of TSLP protein and its genetic instructions (mRNA). The study also looks at other cells involved in allergy and inflammation, such as eosinophils (a type of white blood cell) and mast cells (cells that release chemicals during allergic reactions), to see how they respond over time.
Denmark 
